Business Context and Reporting Period
Company: 3PEA International, Inc. (Note: Request metadata listed "Paysign, Inc.", but the filing text identifies the issuer as 3PEA International, Inc.)
Reporting Period: Quarterly period ended June 30, 2012 (Form 10-Q).
Business Overview: A payment solutions company providing prepaid debit program management and processing services. Primary markets include healthcare reimbursement, pharmaceutical assistance, and corporate incentive rewards. The company is expanding into payroll cards and general-purpose reloadable cards.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2012 | Six Months Ended June 30, 2012 | Balance Sheet (June 30, 2012) |
|---|---|---|---|
| Revenues | $2,549,003 | $4,033,595 | N/A |
| Gross Profit | $515,739 | $778,526 | N/A |
| Gross Margin | 20.2% | 19.3% | N/A |
| Net Income | $1,480,820 | $1,557,160 | N/A |
| Operating Cash Flow | N/A | $170,653 | N/A |
| Cash & Equivalents | N/A | N/A | $117,621 |
| Restricted Cash | N/A | N/A | $5,450,084 |
| Total Current Liabilities | N/A | N/A | $8,841,226 |
| Stockholders' Deficit | N/A | N/A | $(821,938) |
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased significantly by 283% for the three months ended June 30, 2012, compared to the same period in 2011 ($2.55M vs. $0.67M). This was driven by increased processing volume and the launch of eight new plasma donation centers.
- Profitability: Net income surged to $1.48M for the quarter (vs. $59.6k in 2011). This increase is primarily attributable to a non-recurring Gain on Debt Extinguishment of $1,136,055 resulting from the conversion of $1.67M in promissory notes into equity and warrants.
- Operating Income: Operating income improved to $360,468 from $75,513 in the prior year quarter, reflecting higher gross profit despite stable operating expenses.
- Liquidity: Unrestricted cash increased to $117,621 from $63,826 at year-end 2011. However, the company maintains a significant stockholders' deficit of $(821,938).
Guidance, Outlook, and Risks
- Outlook: Management anticipates steady growth over the next 24 months, targeting approximately 25 plasma donation centers for 2012. Pharmaceutical marketing cards remain the primary revenue driver.
- Capital Needs: The company plans to raise additional capital via a private placement to diversify into new market verticals and repay remaining indebtedness. Management believes current cash and anticipated revenues are sufficient for the next 12 months, provided material interest or note payments are not required.
- Debt Strategy: The company intends to convert remaining notes payable into equity. Failure to do so may force the use of raised capital for debt reduction rather than expansion.
- Risks: Revenue from pharmaceutical marketing cards fluctuates widely due to factors outside the company's control, such as program start/stop dates and marketing campaign timing. There is no assurance that additional capital can be raised on acceptable terms.
Investor Verification Checklist
- Debt Conversion Details: Verify the terms of the $1.67M debt conversion into 3.3M shares and warrants, and assess the dilution impact on existing shareholders.
- Restricted Cash: Confirm the nature of the $5.45M in restricted cash and the corresponding "Customer card funding" liability to ensure it does not represent available working capital.
- Revenue Sustainability: Analyze the volatility of pharmaceutical marketing revenue and the specific contribution of the new plasma donation centers to future cash flows.
- Outstanding Debt: Review the remaining $264,400 in notes payable and $538,000 in related party notes to understand repayment obligations and conversion risks.
- Stock Issuance: Verify the valuation of the stock and warrants issued for debt settlement ($0.09/share) against current market conditions.